Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle Osseuse.
Cavazzana-Calvo M, Bordigoni P, Michel G, Esperou H, Souillet G, Leblanc T, Stephan JL, Vannier JP, Mechinaud F, Reiffers J, Vilmer E, Landman-Parker J, Benkerrou M, Baruchel A, Pico J, Bernaudin F, Bergeron C, Plouvier E, Thomas C, Wijdenes J, Lacour B, Blanche S, Fischer A. Cavazzana-Calvo M, et al. Among authors: wijdenes j. Br J Haematol. 1996 Apr;93(1):131-8. doi: 10.1046/j.1365-2141.1996.4831024.x. Br J Haematol. 1996. PMID: 8611446 Clinical Trial.
In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia.
Cavazzana-Calvo M, Jabado N, Bordigoni P, Michel G, Haddad E, Mechinaud F, Landman-Parker J, Leblanc T, Plouvier E, Baruchel A, Stephan JL, Souillet G, Vilmer E, Wijdenes J, Le Deist F, Fischer A. Cavazzana-Calvo M, et al. Among authors: wijdenes j. Leuk Lymphoma. 1997 Dec;28(1-2):103-12. doi: 10.3109/10428199709058336. Leuk Lymphoma. 1997. PMID: 9498709
Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A. Jabado N, et al. Among authors: wijdenes j. Pediatrics. 1996 Sep;98(3 Pt 1):420-8. Pediatrics. 1996. PMID: 8784367
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.
Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A. Haddad E, et al. Among authors: wijdenes j. Blood. 2001 Mar 15;97(6):1590-7. doi: 10.1182/blood.v97.6.1590. Blood. 2001. PMID: 11238096 Free article. Clinical Trial.
Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment.
Tiberghien P, Racadot E, Lioure B, Delain M, Girard A, Wijdenes J, Plouvier E, Flesch M, Cahn JY, Herve P. Tiberghien P, et al. Among authors: wijdenes j. Transplantation. 1991 Sep;52(3):475-80. doi: 10.1097/00007890-199109000-00016. Transplantation. 1991. PMID: 1910217
202 results